Click here to go to the previous page
FDA Enforcement Update: Advertising and Promotion
Program Code:
231
Date:
Tuesday, June 25, 2013
Time:
10:15 AM to 11:45 AM
EST
CHAIR
:
Wayne Pines,
(SCHNON), President, Regulatory Services and Healthcare,
APCO Worldwide Inc., United States
Wayne Pines, President of regulatory services and healthcare at APCO Worldwide, is a consultant on FDA regulatory and media issues and the editor/ author of a dozen books about FDA and crisis management. He formerly was Associate Commissioner for Public Affairs at FDA.
|
SPEAKER
(S):
Thomas Abrams,
MBA,RPh (SPKAGY), Director, Office of Prescription Drug Promotion, CDER,
FDA, United States
Thomas Abrams is the Director of the Office of Prescription Drug Promotion (OPDP), Food and Drug Administration. Before becoming Director of OPDP, Mr. Abrams was Director of the Division of Drug Marketing, Advertising, and Communications.
|
Pamela M. Williamson, MBA,RAC (SPKNON), Senior Vice President, Global Head, Regulatory Affairs and Compliance, Genzyme Corporation, A Sanofi Company, United States
Description
FDA enforcement actions and policy guidances need to be understood by every company because they reflect FDA's priorities and concerns in regulating advertising and promotion. In this forum, an FDA professional and a representative from industry will examine the latest agency enforcement actions and policies and what they mean.